AMG 595

AMG 595 is an investigational antibody-drug conjugate (ADC) developed for the treatment of glioblastoma multiforme (GBM) and other EGFRvIII-positive tumors. It consists of a human monoclonal antibody highly selective for the deletion-mutant epidermal growth factor receptor variant III (EGFRvIII), which is present in a subset of GBM patients, conjugated via a non-cleavable linker to the cytotoxic agent maytansinoid DM1. The mechanism of action involves specific binding to EGFRvIII-expressing tumor cells, internalization into the endo-lysosomal pathway, and subsequent release of DM1, which inhibits tubulin polymerization leading to mitotic arrest and apoptosis in targeted cancer cells. AMG 595 was developed by Amgen (originally Abgenix). Clinical development focused on recurrent glioblastoma multiforme and anaplastic astrocytoma[1][2][3][4][5][6].

Other names

anti-EGFRvIII antibody-drug conjugateanti-EGFRvIII-DM1 immunoconjugateanti-EGFRvIII-DM-1 immunoconjugateanti-EGFRvIII-DM 1 immunoconjugate